Analytica logo

ALT - Analytica News Story

A$0.003 0.0  25.0%

Last Trade - 1:14am

Sector
Healthcare
Size
Micro Cap
Market Cap £3.87m
Enterprise Value £4.12m
Revenue £474k
Position in Universe 1725th / 1912

Analytica Announces Expansion of PeriCoach® Pelvic Health Solution into China

Wed 31st March, 2021 12:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210331:nGNE1XdhCz&default-theme=true

* PeriCoach will be distributed through extensive network of postpartum care
centres, hospitals, pharmacy chains, and online platforms serviced by the
joint venture partners.
* Joint venture will also leverage extensive network of over 30,000 clinicians
in 100 cities to distribute PeriCoach in China.
* Agreement builds upon Analytica’s existing Middle East distribution
partnership to facilitate growth and manufacturing of PeriCoach in
international markets.
* Clinical trial confirms unsupervised PeriCoach treatment is on par with
in-clinic pelvic floor physical therapy for treating stress urinary
incontinence, at a much lower cost.
* PeriCoach provides cost-effective solution to improve quality of life, ease
burden of care and reduce incontinence pad expenditure in postpartum and aging
populations.
BRISBANE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Analytica Limited
(ASX:ALT), the Australian manufacturer of the PeriCoach pelvic floor exercise
system for the treatment of stress urinary incontinence, has entered into a
joint venture (JV) agreement to manufacture, distribute and market the system
in China, Macau, Hong Kong and Taiwan. Analytica partners with Hebei NACOL
Bio-Technology Co., Ltd (Nacol) and Shijiazhuang Biosphere Pty Ltd
(Biosphere), based in Hebei Province.

Nacol key shareholders include two highly experienced Chinese medical
manufacturing and distribution companies, Heibei Aineng Biological Technology
Co., Ltd and Shijiazhuang YST Medical Supplies Co. Ltd.

The JV will register PeriCoach with the Chinese Food and Drug Administration
(CFDA) as a class II medical device. With CFDA clearance, PeriCoach can become
a prescription treatment, initially covering the hospital network in the North
China area.

Expansion into China will support the distribution of PeriCoach to both the
rapidly growing postpartum rehabilitation market and the early-stage
preventative senior market, as one in three women worldwide suffer from stress
urinary incontinence. The agreement furthers Analytica’s strategy to bring
PeriCoach into global markets, building upon growth in the Middle East with
partner Motion Egypt LLC, and pursuit of other partners in North America,
Europe and Southeast Asia outside of China.

PeriCoach is comprised of a medical device, smartphone app and the PeriVault,
the largest pelvic floor muscle exercise database in the world. PeriCoach
includes biofeedback technique guidance technology that helps women correctly
perform pelvic floor exercises, also known as “Kegel” exercises, while the
device and app are being used. Real-world data from PeriCoach patients(1)
shows that nearly 60% of women do not know how to engage these hidden muscles
when they first use the device. PeriCoach technique guidance means
“Kegels” can be done correctly and confidently by any woman in the privacy
of her own home.

A recent independent, peer-reviewed, randomized controlled clinical
trial(2)(,3) performed at the University of New Mexico and published in the
Journal of Female Pelvic Medicine & Reconstructive Surgery concluded that the
PeriCoach biofeedback system, with no formal instruction, is non-inferior and
on par with in-clinic pelvic floor physical therapy in a pelvic floor centre
of excellence, making this system the most cost-effective(4) form of treatment
for stress and mixed urinary incontinence. Watch Video
(https://www.globenewswire.com/Tracker?data=5DPvGbsRdQsLMa1ZQ5IVco_nEPbtLmYGsJIfqO_CKwiKZ6kw_li0STVFrhVuP8kc0p3HFoJIjOLp8rh21Cm5Ig==)
Here.

A photo accompanying this announcement is available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/1d7fc4b0-f47e-4dae-819d-b5db59eb359f

Currently manufactured in Australia, the new PeriCoach manufacturing line for
the Chinese market only is located in the Shijiazhuang Free Trade Zone and
will be listed as one of the major projects in the free trade zone and high
technology zone.

PeriCoach will be distributed through the existing extensive network of
hospitals and postpartum organisations serviced by the JV partners. The JV
partners have collaborated with a leading postpartum care service platform in
China with coverage of 100 cities and more than 30,000 clinical professionals.

In China, 15 million babies are born each year.(5) With the rapid development
of the modern economy, the postpartum rehabilitation industry has grown to
3.95bn yuan pa (US$608M) in 2018, with a compound annual growth rate of
43.9%.(6)

Furthermore, China, as with Western countries, has an aging population among
which 31% of older women experience urinary incontinence, but only 25% of
those currently seek medical assistance.(7) The JV sees a large public health
opportunity for conservative treatment of incontinence in women aged 50-70
years, reducing the quality-of-life impact along with the longer-term economic
burden of aged-care.

The CEO of Aineng, Mr LanJu Xu, will lead the JV and comments: “We have
strong confidence in Analytica’s R&D capabilities and do believe that
Analytica and Nacol can take advantage of each parties’ strengths from this
Joint Venture and achieve a win-win situation. Bringing together Analytica’s
leading technology and Nacol’s extensive industry resources in China, we are
looking forward to witnessing PeriCoach enter this huge market.”

Mr Xu has a strong background in medical devices and materials, including a
track record of 17 class II medical device approvals and completed clinical
trials of two class III medical devices. He is also the Team Lead for Key
Research & Development (R&D) Program of the Ministry of Science and Technology
in China, which is operated by four leading universities and one of the top
three hospitals in China. Additionally, Mr Xu is the lead of the medical
material R&D Center in Nankai University.

Analytica Ltd Chairman, Dr Michael Monsour, comments: “Entering the China
market with such nimble, experienced operators is a major milestone for
Analytica. China is leading the world in recognising the need for effective
postpartum care and is facing the challenge of caring for its large aging
population by using the PeriCoach system to assist women with managing
incontinence. PeriCoach is a proven cost-effective solution that will
dramatically improve quality of life and burden of care for women. We look
forward to the continued exploration of our strategic options to expand the
availability of PeriCoach globally.”

Analytica has recently moved its Australian manufacturing operations and is
looking to re-establish online sales in the US, UK/Ireland, Australia and New
Zealand in the near future. PeriCoach has USFDA 510(k) clearance, Australian
ARTG registration, and CE-marking.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit: www.AnalyticaMedical.com

References
1. Data on file.
2. Analytica Announcement:
https://www.analyticamedical.com/downloads/2020/20201120-ASX-ALT-UoNM-FPMRS.pdf
3. Barnes, Kara Lauren MD*; Cichowski, Sara MD, FACOG, FPMRS†; Komesu, Yuko
M. MD, FACOG, FPMRS*; Jeppson, Peter C. MD, FACOG, FASC, FPMRS*; McGuire,
Brenna MD*; Ninivaggio, Cara S. MD, FPMRS*; Dunivan, Gena C. MD, FACOG, FPMRS*
Home Biofeedback Versus Physical Therapy for Stress Urinary Incontinence,
Female Pelvic Medicine & Reconstructive Surgery: November 16, 2020 - Volume
Publish Ahead of Print - Issue - doi:
10.1097/SPV.0000000000000993: https://journals.lww.com/jpelvicsurgery/Abstract/9000/Home_Biofeedback_Versus_Physical_Therapy_for.99288.aspx
4. White Paper: Health Economics of PeriCoach for Management of Stress Urinary
Incontinence:
https://www.analyticamedical.com/downloads/2020/20201124-ASX-ALT-deWinterWhitepaper.pdf
5. National Bureau of Statistics of China:
https://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A03060D&sj=2020
6. Compound Growth: Overview of China's postpartum rehabilitation equipment
industry in 2019 (report code: 19RI0824) by leadleo Academy
7. Che, X. Y., Wu, S. L., Chen, Y. K., Huang, Y. B., & Yang, Y. (2019).
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health
sciences, 51(4), 706–710.
https://doi.org/10.19723/j.issn.1671-167X.2019.04.019: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433489/
About Analytica Limited

Analytica’s lead product is the PeriCoach(®) System – an e-health
treatment system for women who suffer Stress Urinary Incontinence. This
affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic
floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device
evaluates activity in pelvic floor muscles. This information is transmitted to
a smartphone app and can be loaded to a cloud database where physicians can
monitor patient progress via web portal. This novel system enables physicians
to remotely determine if a woman is performing her pelvic floor exercises and
if these are improving her condition. Strengthening of the pelvic floor
muscles can also potentially improve sexual sensation or satisfaction and
orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and
has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the
treatment of pelvic organ prolapse, a condition that affects up to 1 in 5
women during their lifetime.

Contact:
Geoff Daly, CEO
investorrelations@analyticamedical.com
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.